Optimal timing to retrieve oocytes for fertility preservation in patients with acute myeloid leukemia: two cases of controlled ovarian stimulation using DuoStim with a literature review

Gynecol Endocrinol. 2023 Dec;39(1):2217262. doi: 10.1080/09513590.2023.2217262.

Abstract

Fertility preservation (FP) for hematological malignancies is difficult because immediate chemotherapy is needed after diagnosis. We report two cases of acute myeloid leukemia (AML) treated with controlled ovarian stimulation (COS) and oocyte cryopreservation using DuoStim after first-line chemotherapy. In Cases 1 and 2, COS and oocyte retrieval (OR) were performed using DuoStim 116 and 51 days after first-line chemotherapy, respectively, and 14 and 6 unfertilized oocytes, respectively, were cryopreserved. Another round of COS and OR was performed using the random-start method 82 days after first-line chemotherapy, and 22 unfertilized oocytes were cryopreserved. DuoStim is useful to maximize OR for patients with a short interval for FP. Many oocytes can be retrieved depending on the timing of recruitment from primary to secondary follicles, although ovarian reserve capacity declines immediately after first-line chemotherapy. Aggressive FP should be performed before allogeneic hematopoietic stem cell transplantation becomes necessary.

Keywords: Acute myeloid leukemia; DuoStim; chemotherapy; double stimulation; fertility preservation; oocyte retrieval; progestin-primed ovarian stimulation; random-start ovarian stimulation.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Cryopreservation / methods
  • Female
  • Fertility Preservation* / methods
  • Humans
  • Leukemia, Myeloid, Acute* / complications
  • Leukemia, Myeloid, Acute* / drug therapy
  • Oocyte Retrieval / methods
  • Oocytes / physiology
  • Ovulation Induction / methods